UK Medical Oncology Training Portal

Evidence-based resources for ST3-ST7 trainees, clinical fellows & junior doctors

Quick Access Dashboard

Emergency Protocols

Febrile neutropenia, SVCO, spinal cord compression

Immunotherapy Toxicity

ESMO & Clatterbridge guidelines

Molecular Markers

Diagnostic, prognostic & predictive biomarkers

SACT Protocols

St Luke's style quick reference sheets

Landmark Trials Library

Comprehensive database of practice-changing oncology trials organized by tumor site and clinical setting.

MOSAIC Trial

Phase III
Year: 2004 | N: 2,246
Population: Stage II/III colon cancer post-surgery
Intervention: FOLFOX4 vs 5-FU/LV
Primary Endpoint: Disease-free survival
Key Results: 6-year DFS: 72.9% vs 67.1% (HR 0.80, p=0.003)
Practice Change: Established FOLFOX as standard adjuvant therapy for stage III colon cancer
Key Toxicity: Grade 3+ sensory neuropathy (12.4%)
PubMed Link

KATHERINE Trial

Phase III
Year: 2019 | N: 1,486
Population: HER2+ breast cancer with residual invasive disease post-neoadjuvant
Intervention: T-DM1 vs trastuzumab
Primary Endpoint: Invasive disease-free survival
Key Results: 3-year iDFS: 88.3% vs 77.0% (HR 0.50, p<0.001)
Practice Change: T-DM1 became standard adjuvant therapy for HER2+ breast cancer with residual disease
Key Toxicity: Grade 3+ thrombocytopenia (5.7%)
PubMed Link

KEYNOTE-189

Phase III
Year: 2018 | N: 616
Population: Metastatic nonsquamous NSCLC, EGFR/ALK wild-type
Intervention: Pembrolizumab + carboplatin + pemetrexed vs placebo + chemotherapy
Primary Endpoint: Overall survival and progression-free survival
Key Results: Median OS: 22.0 vs 10.7 months (HR 0.49, p<0.001)
Practice Change: Established pembrolizumab + chemotherapy as first-line standard for non-squamous NSCLC
Key Toxicity: Grade 3-5 AEs (71.9% vs 66.8%)
PubMed Link

CheckMate 067

Phase III
Year: 2015 | N: 945
Population: Previously untreated advanced melanoma
Intervention: Nivolumab + ipilimumab vs nivolumab vs ipilimumab
Primary Endpoint: Progression-free survival and overall survival
Key Results: 5-year OS: 52% vs 44% vs 26% respectively
Practice Change: Combination immunotherapy became standard for advanced melanoma
Key Toxicity: Grade 3-4 AEs (59% combination vs 21% nivolumab)
PubMed Link

Guidelines & Clinical Pathways

Evidence-based decision algorithms aligned with NCCN, ESMO, and NICE guidelines.

Decision Algorithms

Colorectal Cancer
NCCN & ESMO aligned pathways
Breast Cancer
Molecular subtype-specific
Lung Cancer
Histology & biomarker driven
Upper GI Cancers
HER2 & MSI testing included

Molecular Markers

Diagnostic Markers
Tumor identification & classification
Prognostic Markers
Disease outcome prediction
Predictive Markers
Treatment response prediction

SACT Protocols

FOLFOX
Colorectal standard regimen
AC-T
Breast adjuvant chemotherapy
Carboplatin-Pemetrexed
Non-squamous NSCLC

Clinic Templates

New Patient Proforma

  • • Performance status assessment
  • • Comorbidity evaluation
  • • Staging & molecular markers
  • • Treatment options discussion
  • • Consent documentation

Follow-up Proforma

  • • Toxicity assessment (CTCAE v5)
  • • Response evaluation
  • • Dose modifications
  • • Supportive care needs
  • • Next cycle planning

Acute Oncology & Toxicity Management

Comprehensive toxicity navigator and emergency protocols for immediate clinical use.

Toxicity Navigator

Emergency Protocols

Febrile Neutropenia

Immediate assessment & antibiotic protocol

Spinal Cord Compression

Urgent MRI & dexamethasone protocol

SVCO Syndrome

Airway assessment & management

Immunotherapy Toxicity Quick Guide

Based on ESMO & Clatterbridge guidelines

Skin Toxicity

Rash, pruritus, vitiligo

GI Toxicity

Colitis, diarrhea, hepatitis

Endocrine

Thyroid, adrenal, pituitary

Pulmonary

Pneumonitis, ILD

Case-Based Teaching Packs

Febrile Neutropenia

Case-based approach with MASCC scoring

Immune Colitis

Pathophysiology & management algorithm

Tumor Lysis Syndrome

Prevention & treatment protocols

MDT Case Presentation Templates

Tumor-site specific templates for structured multidisciplinary team presentations.

Colorectal MDT Template

Demographics & Performance Status
Primary Tumor Details (T, location, grade)
Nodal Status & Staging (TNM 8th edition)
Molecular Markers (MSI, RAS, BRAF)
Radiology Review (CT, MRI, PET)
Treatment Recommendation

Breast MDT Template

Age, Menopausal Status, Family History
Tumor Characteristics (Size, Grade, LVI)
Receptor Status (ER, PR, HER2, Ki67)
Nodal Assessment (SNB/ALND results)
Genomic Testing (OncotypeDX, Mammaprint)
Surgical & Systemic Treatment Plan

Template Preview

Patient: [Age] year old [M/F]
Performance Status: ECOG [0-4]
Comorbidities: [List relevant]
Primary Tumor:
• Site: [Anatomical location]
• Size: [Dimensions in cm]
• Histology: [Type and grade]
• T stage: [TNM 8th edition]
Nodal Status:
• Clinical: [cN stage]
• Pathological: [pN stage if available]
• Number involved: [X/Y nodes]
Molecular/Biomarkers:
• [Relevant markers for tumor type]
• [Testing status and results]
MDT Recommendation:
[Treatment plan with rationale]

Additional Tumor-Specific Templates

Lung Cancer

Histology & biomarker focused

Upper GI

HER2 & MSI testing included

Ovarian

BRCA & HRD testing pathway

Renal/Urology

Risk stratification focused

ARCP Portfolio Builder

Structured evidence collection and portfolio management for annual review.

Evidence Categories

Clinical Experience
Case logs & procedures
15/20
Teaching & Training
Presentations & courses
8/12
Quality Improvement
Audits & projects
2/6
Research
Publications & presentations
4/4

Portfolio Tools

Progress Tracking

Overall Progress 73%
Clinical Competencies ✓ Complete
Teaching Portfolio ◐ In Progress
Research Evidence ✓ Complete
Quality Improvement ◯ Needs Attention

Recent Portfolio Entries

Complex Colorectal Case
Metastatic disease management - Added 2 days ago
Immunotherapy Teaching Session
Junior doctor education - Added 1 week ago